DFX Intelligence

Data Factory

VentureFirmmulti stage vc · probableregistered_investment_adviser

Catalio Capital Management, LP

Venture Capital

New York, NY

Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:cd2ebf2c-8a27-44f9-ac56-a9ffc822f315

Data as of Sep 17, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 20, 2026, 8:45 PM UTC and rebuilt at most every 15 minutes.

Relationships: 225
Dated events: 30
On other graphs: 3
Observed: Sep 12, 2026 to Sep 17, 2026
57 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Independent Sponsorsidentity

Catalio Capital Management, LP

Capital provider to sponsors · shared crd

Private Equityidentity

Catalio Capital Management, LP

Private equity manager · shared crd

RIA / Wealth Managementidentity

CATALIO CAPITAL MANAGEMENT, LP

Registered adviser · shared crd

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 28
Vintages: 2016 to 2026
Reported GAV: $905Mgross asset value on Form ADV; never dry powder
Regulatory AUM: $2.2B
Funds with fundraising evidence: 0derived
Investments: 101
Portfolio companies: 100
Investments, 12m: 101
Partner-attributed: 0
People: 84
Investment professionals: 60derived
Co-investors: 0derived
LP relationships: 0
Stated sectors: ai,enterprise_software,healthcare,biotech,medtechas stated by the firm
Stated stages: multi_stage
Stated geography: new york,washington dc
Latest Form D: Jun 10, 2026
Latest ADV filing: Mar 31, 2026
Website: cataliocapital.com

Funds

Fund	Vintage	Lifecycle	Form D sold	GAV
Catalio Access Fund X, LLC	2026	Newly closed	$20.3M	n/a
Catalio Access Fund XI, LLC	2026	Newly closed	$14.3M	n/a
Catalio Access Fund VIII, LLC	2026	Newly closed	$25.0M	n/a
Catalio Access Fund IX, LLC	2026	Newly closed	$12.3M	n/a
Catalio Genesis Fund X, LLC	2026	Newly closed	$19.1M	n/a
Catalio Genesis Fund VI, LLC	2025	Newly closed	$15.5M	n/a
Catalio Genesis Fund VIII, LLC	2025	Newly closed	$15.2M	n/a
Catalio Genesis Fund IX, LLC	2025	Newly closed	$8.6M	n/a
Catalio Structured Opportunities Aiv I LP	2024	Early deployment	n/a	$30.7M
Catalio Access Fund VII, LLC	2024	Early deployment	$5.0M	n/a
Catalio Genesis Fund V, LLC	2024	Early deployment	$11.5M	n/a
Catalio Nexus Fund IV, LP	2023	Fundraising	$358M	$191M
Catalio Special Opportunities Fund III, LLC	2022	Wound down	n/a	$1.5M
Catalio Access Fund VI, LLC	2022	Active deployment	$8.2M	$8.3M
Catalio Genesis Fund IV, LLC	2022	Active deployment	$10.1M	$11.3M
Catalio Special Opportunities Fund I, LLC	2021	Mature	n/a	$736,630
Catalio Genesis Fund I, LLC	2021	Mature	n/a	$46.8M
Catalio Access Fund V, LLC	2021	Mature	$16.1M	$15.5M
Catalio Nexus Sidecar I, LLC	2021	Wound down	n/a	$573
Catalio Nexus Fund III, LP	2021	Mature	$384M	$365M
Catalio Genesis Fund III, LLC	2021	Mature	$35.0M	$35.8M
Catalio Genesis Fund II, LLC	2021	Mature	$46.2M	$43.4M
Catalio Access Fund II, LLC	2021	Wound down	n/a	$69,262
Catalio Access Fund III, LLC	2021	Wound down	n/a	$19.9M
Catalio Nexus Fund I, LP	2016	Harvest	$11.0M	$9.3M

Investments

round size is never this investor's check

Company	State	Stage	Round size	Partner	Attribution	Observed
Amalgam Rx, Inc.	De	n/a	n/a	n/a	Unknown	Sep 16, 2026
ArriVent IPO in	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Ashvattha Therapeutics Exit in	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Atai Life Sciences IPO in	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Audicus Loan Repayment in	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Automata	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Avalyn Pharma IPO in	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
AVAVA, Inc.	Ma	n/a	n/a	n/a	Unknown	Sep 16, 2026
Axena Health, Inc.	Ma	n/a	n/a	n/a	Unknown	Sep 16, 2026
Bayesian Health	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Beacon Biosignals, Inc.	Ma	n/a	n/a	n/a	Unknown	Sep 16, 2026
BigHat Biosciences, Inc.	CA	n/a	n/a	n/a	Unknown	Sep 16, 2026
Blackrock Neurotech	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
b.well	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Cage Pharmaceuticals, Inc.	NY	n/a	n/a	n/a	Unknown	Sep 16, 2026
Cambrian BioPharma Inc	NY	n/a	n/a	n/a	Unknown	Sep 16, 2026
Carbon Health	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Cartography	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Celsius Therapeutics M&A in	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Centenara Labs	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Centrexion Therapeutics Corp	Ma	n/a	n/a	n/a	Unknown	Sep 16, 2026
Character Biosciences, Inc.	Nj	n/a	n/a	n/a	Unknown	Sep 16, 2026
Claris Bio	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Clasp Therapeutics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Alentis Therapeutics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026

Co-investors

pairs come only from shared rounds and listings

Investor	Co-investor	Shared deals	Shared companies	Last observed	Strength
Arch Venture Partners	Catalio Capital Management, LP	3	3	Sep 16, 2026	Recurring
Artis Capital Management, L.P.	Catalio Capital Management, LP	2	2	Sep 16, 2026	Recurring
Hummingbird Ventures V US GP LLC	Catalio Capital Management, LP	2	2	Sep 16, 2026	Recurring
Khosla Ventures, LLC	Catalio Capital Management, LP	2	2	Sep 16, 2026	Recurring
Catalio Capital Management, LP	Artis Ventures Management, L.P.	2	2	Sep 16, 2026	Recurring
AIR Street Capital II LP	Catalio Capital Management, LP	2	2	Sep 16, 2026	Recurring
Sempervirens Ventures LLC	Catalio Capital Management, LP	1	1	Sep 16, 2026	One time
Breakout Management, LLC	Catalio Capital Management, LP	1	1	Sep 16, 2026	One time
Femhealth Ventures Management LLC	Catalio Capital Management, LP	1	1	Sep 16, 2026	One time
Bioeconomy Capital GP, LLC	Catalio Capital Management, LP	1	1	Sep 3, 2026	One time
Perceptive Advisors	Catalio Capital Management, LP	1	1	Sep 3, 2026	One time
LUX Capital Management, LLC	Catalio Capital Management, LP	1	1	Sep 16, 2026	One time
137 Ventures Management, LLC	Catalio Capital Management, LP	1	1	Sep 16, 2026	One time
Nvidia	Catalio Capital Management, LP	1	1	Sep 3, 2026	One time
Eli Lilly	Catalio Capital Management, LP	1	1	Sep 3, 2026	One time

Relationships

showing 80 of 225

Invested in (80)

→ ImmunaiCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ PrognomIQ, Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Dianthus IPO inCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ ImbriaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Octant BioCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Port TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Beacon Biosignals, Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Cresilon Loan RepaymentCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Erisyon Exit inCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Iambic Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Lila SciencesCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Noetik Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Paige AI M&ACompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Pink DxCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Ashvattha Therapeutics Exit inCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Bayesian HealthCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ CartographyCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Compass Pathways IPO inCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ eNeuraCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ EnvedaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ GeorgiamuneCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Hippocratic AICompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ KaileraCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ LifeSprout, Inc. M&ACompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ MindX Exit inCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ NextPoint Therapeutics, Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ OpenEvidenceCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ OspriCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Perfuse Therapeutics M&A inCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Pillar Biosciences Loan Repayment inCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
and 50 more

Dated events

28 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Jun 1, 2021
Person joined
Olga Eduardovna Maltseva joined Schedule A of Catalio Capital Management, LP as Chief Compliance Officer And Head Of Operations
Form ADVobserved 8 days ago
Occurred
Sep 2, 2020
Adviser's first ADV filing
Catalio Capital Management, LP first filed Form ADV (ERA, venture capital fund adviser exemption)
Form ADVobserved 8 days ago

Show 28 bookkeeping events

First seen by DFX
Sep 15, 2026
date not stated
Elektrofi M&A: acquired (acquirer not named) on or before 2026-09-15 (no date published), per Catalio Capital Management, LP's portfolio page
First seen by DFX
Sep 15, 2026
date not stated
Paige AI M&A: acquired (acquirer not named) on or before 2026-09-15 (no date published), per Catalio Capital Management, LP's portfolio page
First seen by DFX
Sep 15, 2026
date not stated
LifeSprout, Inc. M&A: acquired (acquirer not named) on or before 2026-09-15 (no date published), per Catalio Capital Management, LP's portfolio page
First seen by DFX
Sep 15, 2026
date not stated
Perfuse Therapeutics M&A in: acquired (acquirer not named) on or before 2026-09-15 (no date published), per Catalio Capital Management, LP's portfolio page
First seen by DFX
Sep 15, 2026
date not stated
Celsius Therapeutics M&A in: acquired (acquirer not named) on or before 2026-09-15 (no date published), per Catalio Capital Management, LP's portfolio page
First seen by DFX
Sep 15, 2026
date not stated
Sherlock Biosciences M&A in: acquired (acquirer not named) on or before 2026-09-15 (no date published), per Catalio Capital Management, LP's portfolio page
Occurred
Mar 26, 2024
Catalio Structured Opportunities Aiv I LP first reported on Form ADV by Catalio Capital Management, LP (Other Private Fund), GAV $30,659,590
Occurred
Mar 26, 2024
Catalio Special Opportunities Fund III, LLC no longer reported on Form ADV by Catalio Capital Management, LP
Occurred
Mar 26, 2024
Catalio Nexus Fund IV, LP first reported on Form ADV by Catalio Capital Management, LP (Private Equity Fund), GAV $191,152,006
Occurred
Mar 30, 2023
Catalio Genesis Fund IV, LLC first reported on Form ADV by Catalio Capital Management, LP (Venture Capital Fund), GAV $10,091,409
Occurred
Mar 30, 2023
Catalio Access Fund VI, LLC first reported on Form ADV by Catalio Capital Management, LP (Venture Capital Fund), GAV $8,252,549
Occurred
Mar 30, 2023
Catalio Access Fund II, LLC no longer reported on Form ADV by Catalio Capital Management, LP
Occurred
Mar 30, 2023
Catalio Nexus Sidecar I, LLC no longer reported on Form ADV by Catalio Capital Management, LP
Occurred
Mar 30, 2023
Catalio Access Fund III, LLC no longer reported on Form ADV by Catalio Capital Management, LP
Occurred
Mar 31, 2022
Catalio Access Fund I, LLC no longer reported on Form ADV by Catalio Capital Management, LP
Occurred
Mar 31, 2022
Catalio Nexus Fund III, LP first reported on Form ADV by Catalio Capital Management, LP (Private Equity Fund), GAV $309,552,150
Occurred
Mar 31, 2022
Catalio Genesis Fund III, LLC first reported on Form ADV by Catalio Capital Management, LP (Venture Capital Fund), GAV $35,612,840
Occurred
Mar 31, 2022
Catalio Access Fund V, LLC first reported on Form ADV by Catalio Capital Management, LP (Venture Capital Fund), GAV $16,326,983
Occurred
Mar 31, 2022
Catalio Special Opportunities Fund III, LLC first reported on Form ADV by Catalio Capital Management, LP (Venture Capital Fund), GAV $4,041,913
Occurred
Mar 31, 2022
Catalio Genesis Fund II, LLC first reported on Form ADV by Catalio Capital Management, LP (Venture Capital Fund), GAV $47,269,053
Occurred
Mar 31, 2021
Catalio Nexus Sidecar I, LLC first reported on Form ADV by Catalio Capital Management, LP (Venture Capital Fund)
Occurred
Mar 31, 2021
Catalio Genesis Fund I, LLC first reported on Form ADV by Catalio Capital Management, LP (Venture Capital Fund), GAV $39,975,000
Occurred
Mar 31, 2021
Catalio Special Opportunities Fund I, LLC first reported on Form ADV by Catalio Capital Management, LP (Venture Capital Fund), GAV $1,541,250
Occurred
Mar 31, 2021
Catalio Access Fund III, LLC first reported on Form ADV by Catalio Capital Management, LP (Venture Capital Fund), GAV $15,033,954
Occurred
Mar 31, 2021
Catalio Access Fund II, LLC first reported on Form ADV by Catalio Capital Management, LP (Venture Capital Fund), GAV $10,851,560
Occurred
Sep 2, 2020
Catalio Nexus Fund I, LP first reported on Form ADV by Catalio Capital Management, LP (Venture Capital Fund), GAV $16,785,889
Occurred
Sep 2, 2020
Catalio Nexus Fund II, LP first reported on Form ADV by Catalio Capital Management, LP (Venture Capital Fund), GAV $18,557,422
Occurred
Sep 2, 2020
Catalio Access Fund I, LLC first reported on Form ADV by Catalio Capital Management, LP (Venture Capital Fund), GAV $12,250,000

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 website (Form ADV) · as of 2026-09-12

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Venture Capital
Canonical id: dfx:vc:cd2ebf2c-8a27-44f9-ac56-a9ffc822f315
First observed: Sep 12, 2026
Last observed: Sep 17, 2026 3 days ago
Source families: Federal regulator filings, Firm and issuer disclosures
3 registered feeds stand behind this record; each fact above carries its own dates and, where the publisher serves one, its document.
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

Catalio Capital Management, LP

Venture Capital

New York, NY

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:cd2ebf2c-8a27-44f9-ac56-a9ffc822f315

Data as of Sep 17, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 20, 2026, 8:45 PM UTC and rebuilt at most every 15 minutes.

Fund

Vintage

Lifecycle

Form D sold

GAV

LPs

Catalio Access Fund X, LLC

2026

Newly closed

$20.3M

n/a

Catalio Access Fund XI, LLC

2026

Newly closed

$14.3M

n/a

Catalio Access Fund VIII, LLC

2026

Newly closed

$25.0M

n/a

Catalio Access Fund IX, LLC

2026

Newly closed

$12.3M

n/a

Catalio Genesis Fund X, LLC

2026

Newly closed

$19.1M

n/a

Catalio Genesis Fund VI, LLC

2025

Newly closed

$15.5M

n/a

Catalio Genesis Fund VIII, LLC

2025

Newly closed

$15.2M

n/a

Catalio Genesis Fund IX, LLC

2025

Newly closed

$8.6M

n/a

Catalio Structured Opportunities Aiv I LP

2024

Early deployment

n/a

$30.7M

Catalio Access Fund VII, LLC

2024

Early deployment

$5.0M

n/a

Catalio Genesis Fund V, LLC

2024

Early deployment

$11.5M

n/a

Catalio Nexus Fund IV, LP

2023

Fundraising

$358M

$191M

Catalio Special Opportunities Fund III, LLC

2022

Wound down

n/a

$1.5M

Catalio Access Fund VI, LLC

2022

Active deployment

$8.2M

$8.3M

Catalio Genesis Fund IV, LLC

2022

Active deployment

$10.1M

$11.3M

Catalio Special Opportunities Fund I, LLC

2021

Mature

n/a

$736,630

Catalio Genesis Fund I, LLC

2021

Mature

n/a

$46.8M

Catalio Access Fund V, LLC

2021

Mature

$16.1M

$15.5M

Catalio Nexus Sidecar I, LLC

2021

Wound down

n/a

$573

Catalio Nexus Fund III, LP

2021

Mature

$384M

$365M

Catalio Genesis Fund III, LLC

2021

Mature

$35.0M

$35.8M

Catalio Genesis Fund II, LLC

2021

Mature

$46.2M

$43.4M

Catalio Access Fund II, LLC

2021

Wound down

n/a

$69,262

Catalio Access Fund III, LLC

2021

Wound down

n/a

$19.9M

Catalio Nexus Fund I, LP

2016

Harvest

$11.0M

$9.3M

Company

State

Stage

Round size

Partner

Attribution

Observed

Amalgam Rx, Inc.

n/a

Unknown

Sep 16, 2026

ArriVent IPO in

n/a

Unknown

Sep 16, 2026

Ashvattha Therapeutics Exit in

n/a

Unknown

Sep 16, 2026

Atai Life Sciences IPO in

n/a

Unknown

Sep 16, 2026

Audicus Loan Repayment in

n/a

Unknown

Sep 16, 2026

Automata

n/a

Unknown

Sep 16, 2026

Avalyn Pharma IPO in

n/a

Unknown

Sep 16, 2026

AVAVA, Inc.

n/a

Unknown

Sep 16, 2026

Axena Health, Inc.

n/a

Unknown

Sep 16, 2026

Bayesian Health

n/a

Unknown

Sep 16, 2026

Beacon Biosignals, Inc.

n/a

Unknown

Sep 16, 2026

BigHat Biosciences, Inc.

n/a

Unknown

Sep 16, 2026

Blackrock Neurotech

n/a

Unknown

Sep 16, 2026

b.well

n/a

Unknown

Sep 16, 2026

Cage Pharmaceuticals, Inc.

n/a

Unknown

Sep 16, 2026

Cambrian BioPharma Inc

n/a

Unknown

Sep 16, 2026

Carbon Health

n/a

Unknown

Sep 16, 2026

Cartography

n/a

Unknown

Sep 16, 2026

Celsius Therapeutics M&A in

n/a

Unknown

Sep 16, 2026

Centenara Labs

n/a

Unknown

Sep 16, 2026

Centrexion Therapeutics Corp

n/a

Unknown

Sep 16, 2026

Character Biosciences, Inc.

n/a

Unknown

Sep 16, 2026

Claris Bio

n/a

Unknown

Sep 16, 2026

Clasp Therapeutics

n/a

Unknown

Sep 16, 2026

Alentis Therapeutics

n/a

Unknown

Sep 16, 2026

Investor

Co-investor

Shared deals

Shared companies

Last observed

Strength

Arch Venture Partners

Catalio Capital Management, LP

Sep 16, 2026

Recurring

Artis Capital Management, L.P.

Catalio Capital Management, LP

Sep 16, 2026

Recurring

Hummingbird Ventures V US GP LLC

Catalio Capital Management, LP

Sep 16, 2026

Recurring

Khosla Ventures, LLC

Catalio Capital Management, LP

Sep 16, 2026

Recurring

Catalio Capital Management, LP

Artis Ventures Management, L.P.

Sep 16, 2026

Recurring

AIR Street Capital II LP

Catalio Capital Management, LP

Sep 16, 2026

Recurring

Sempervirens Ventures LLC

Catalio Capital Management, LP

Sep 16, 2026

One time

Breakout Management, LLC

Catalio Capital Management, LP

Sep 16, 2026

One time

Femhealth Ventures Management LLC

Catalio Capital Management, LP

Sep 16, 2026

One time

Bioeconomy Capital GP, LLC

Catalio Capital Management, LP

Sep 3, 2026

One time

Perceptive Advisors

Catalio Capital Management, LP

Sep 3, 2026

One time

LUX Capital Management, LLC

Catalio Capital Management, LP

Sep 16, 2026

One time

137 Ventures Management, LLC

Catalio Capital Management, LP

Sep 16, 2026

One time

Nvidia

Catalio Capital Management, LP

Sep 3, 2026

One time

Eli Lilly

Catalio Capital Management, LP

Sep 3, 2026

One time